Cocrystal Pharma
NASDAQ: COCPTucker, US · Delaware corporation
Cocrystal Pharma is a clinical-stage biotechnology company that discovers and develops broad-spectrum antiviral drugs targeting the replication process of viruses including influenza, coronaviruses (SARS-CoV-2, MERS), norovirus, and hepatitis C. It uses structure-based drug discovery technologies to develop treatments for serious and chronic viral diseases such as influenza, COVID-19, hepatitis C, and norovirus-caused gastroenteritis.
Founders & leadership
RF
RAYMOND F SCHINAZICo-founder
SL
SAM LEECo-founder
BK
Brian KellerCo-founder
WA
WALT ADDISON LINSCOTTExecutive
DL
DOUGLAS L MAYERSExecutive
CD
CURTIS DALEExecutive
JA
JEFFREY A MECKLERExecutive
GA
GARY A WILCOXExecutive
EM
Elliot M. MazaExecutive
CO
Christian OertleExecutive
DF
Daniel FisherExecutive
Board
JH
JANE H HSIAOBoard director
Reported raises · per SEC filings
Form D private placements$18.7M disclosed across 7 of 8 rounds · 2012–2017
▶$3MraisedMay 2017 · 3 investors · PharmaceuticalsRule 506(b)
▶$3MraisedMay 2017 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Steven D. RubinDirector
- David S. BlockDirector
- Raymond F. SchinaziDirector
- Phillip FrostDirector
- Sam LeeExecutive Officer
- Jane H. HsiaoDirector
- James MartinExecutive Officer
- Gary WilcoxExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Apr 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedSep 2016 · 4 investors · PharmaceuticalsRule 506(b)
▶$4MraisedSep 2016 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Phillip FrostDirector
- Sam LeeExecutive Officer
- Jane H. HsiaoDirector
- Curtis DaleExecutive Officer
- Gary WilcoxExecutive Officer, Director
- Raymond F. SchinaziDirector
- David S. BlockDirector
- Steven D. RubinDirector
- Walt Addison LinscottExecutive Officer
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedMar 2016 · 12 investors · PharmaceuticalsRule 506(b)
▶$5MraisedMar 2016 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- JANE H HSIAODirector
- WALT ADDISON LINSCOTTExecutive Officer
- PHILLIP A FROSTDirector
- RAYMOND F SCHINAZIDirector
- DOUGLAS L MAYERSExecutive Officer
- STEVEN D RUBINDirector
- CURTIS DALEExecutive Officer
- SAM LEEExecutive Officer
- JEFFREY A MECKLERExecutive Officer, Director
- DAVID S BLOCKDirector
- GARY A WILCOXDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.8MraisedJan 2014 · 8 investors · BiotechnologyRule 506(b)
▶$2.8MraisedJan 2014 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Phillip FrostDirector
- Steven RubinDirector
- Jane HsiaoDirector
- Sam LeeExecutive Officer, Director
- Gerald McGuireExecutive Officer
- Gary WilcoxExecutive Officer, Director
- Roger KornbergDirector
- Offering amount
- $2.8M
- Amount sold
- $2.8M
- Sales commissions
- $125K
- First sale
- Jan 2014
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶Undisclosed amountofferedJan 2014 · 23 investors · BiotechnologyRule 506(b)
▶Undisclosed amountofferedJan 2014 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jane HsiaoDirector
- Roger KornbergDirector
- Sam LeeExecutive Officer, Director
- Phillip FrostDirector
- Gary WilcoxExecutive Officer, Director
- Gerald McGuireExecutive Officer
- Steven RubinDirector
- First sale
- Jan 2014
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$1MraisedMar 2012 · 1 investors · PharmaceuticalsRule 506(b)
▶$1MraisedMar 2012 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christian OertleExecutive Officer
- Roberto Prego-NovoDirector
- Elliot M. MazaExecutive Officer, Director
- Brian KellerExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Mar 2012
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06
▶$2.3MraisedMar 2012 · 3 investors · PharmaceuticalsRule 506(b)
▶$2.3MraisedMar 2012 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Elliot M. MazaExecutive Officer, Director
- Brian KellerExecutive Officer, Director
- Christian OertleExecutive Officer
- Roberto Prego-NovoDirector
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- First sale
- Feb 2012
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06
▶$650KraisedJan 2012 · 3 investors · PharmaceuticalsRule 506(b)
▶$650KraisedJan 2012 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Brian KellerExecutive Officer, Director
- Elliot M. MazaExecutive Officer
- Roberto Prego-NovoDirector
- Christian OertleExecutive Officer
- Daniel FisherExecutive Officer, Director
- Offering amount
- $650K
- Amount sold
- $650K
- First sale
- Jan 2012
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Robinhood16 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
TradingView15 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Seeking Alpha15 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Medscape14 shared keywordsMedscape is an online medical information platform providing clinical news, expert perspectives, case studies, quizzes, and reference material across specialties such as cardiology, oncology, neurology, and psychiatry. It serves physicians, nurses, pharmacists, residents, and medical students.
Companies competing with Cocrystal Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Cocrystal Pharma do?
- Cocrystal Pharma is a clinical-stage biotechnology company that discovers and develops broad-spectrum antiviral drugs targeting the replication process of viruses including influenza, coronaviruses (SARS-CoV-2, MERS), norovirus, and hepatitis C. It uses structure-based drug discovery technologies to develop treatments for serious and chronic viral diseases such as influenza, COVID-19, hepatitis C, and norovirus-caused gastroenteritis.
- Who founded Cocrystal Pharma?
- Cocrystal Pharma was founded by RAYMOND F SCHINAZI, SAM LEE, Brian Keller.
- How much funding has Cocrystal Pharma raised?
- Cocrystal Pharma has disclosed $18.7M raised across 7 of its 8 known rounds.
- Where is Cocrystal Pharma headquartered?
- Cocrystal Pharma is headquartered in Tucker, US.